KZIA (Kazia Therapeutics) ROCE %: -139.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KZIA Kazia Therapeutics Ltd KZIA
33 GF Score
Price $12.00
! 5 Warning Signs
View Full Analysis

What is Kazia Therapeutics ROCE %?

Kazia Therapeutics KZIA -2.60% 33 ROCE % is -139.30% as of Dec. 2025. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kazia Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was -139.30%.

Kazia Therapeutics  (NAS:KZIA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kazia Therapeutics ROCE % Related Terms

Kazia Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Kazia Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kazia Therapeutics ROCE % Chart

Kazia Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.93 -59.91 -94.59 -344.40 0.00

Kazia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.69 -875.93 0.00 0.00 -139.30
KZIA
33GF Score
Kazia Therapeutics Ltd KZIA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kazia Therapeutics ROCE % Calculation

Kazia Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-9.256/( ( (14.333 - 17.129) + (3.946 - 9.149) )/ 2 )
=-9.256/( (-2.796+-5.203)/ 2 )
=-9.256/-3.9995
=231.43 %

Kazia Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-18.006/( ( (3.946 - 9.149) + (47.251 - 16.195) )/ 2 )
=-18.006/( ( -5.203 + 31.056 )/ 2 )
=-18.006/12.9265
=-139.30 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -139.30% mean?
Kazia Therapeutics (KZIA) has a ROCE % of -139.30% as of Dec. 2025.
Is Kazia Therapeutics' ROCE % too high?
Kazia Therapeutics' current ROCE % is -139.30%. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' ROCE % compare to OKUR and TNYA?
Kazia Therapeutics' ROCE % of -139.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Kazia Therapeutics's current ROCE % is -139.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current ROCE % of -139.30%. The current ROCE % is -139.30%. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current ROCE % is -139.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kazia Therapeutics Business Description

Address 300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score

Get the complete analysis for KZIA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.00
Price